Animal modeling of cancer pathology and studying tumor response to therapy

Current Drug Targets

Volumn 13, Issue 12, 2012, Pages 1535-1547

  Langdon, Simon P ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Canine; Genetically engineered mice; Model; Murine; Preclinical; Transplantable; Xenograft

Indexed keywords

CELECOXIB; CETUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EFLORNITHINE; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; FLURBIPROFEN; FLUTAMIDE; GEFITINIB; GEMCITABINE; GENISTEIN; GW 654652; NERATINIB; PERTUZUMAB; PROTEIN P53; RAPAMYCIN; RESVERATROL; RETINOIC ACID; SELENIUM; TAMOXIFEN; TOCERANIB; TOREMIFENE; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER MODEL; CANCER TISSUE; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MASTOCYTOMA; NEOPLASM; NONHUMAN; NUDE MOUSE; OSTEOSARCOMA; OVARY CANCER; PANCREAS CARCINOMA; PHENOTYPE; PROSTATE CANCER; REVIEW; TRANSGENIC ANIMAL; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CATS; CELL LINE, TUMOR; DOGS; DRUG DESIGN; GENOTYPE; HUMANS; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; PHENOTYPE; RATS; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84870207027     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803530152     Document Type: Review

References (148)

1. Sugitt M, Bibby MC. 50 years of preclinical drug screening: empirical to target-driven approaches. Clin Cancer Res 2005; 11: 971-981.
2. Damia G, D'Incalci M. Contemporary preclinical development of anticancer agents - what are the optimal preclinical models? Eur J Cancer 2009; 45: 2768-2781.
3. Sausville EA, Burger AM. Contributions of Human Tumor Xenografts to Anticancer Drug Development. Cancer Res 2006; 66: 3351-3354.
4. Teicher BA. Tumor models for efficacy determination. Mol Cancer Ther 2006; 5: 2435-2443.
5. Tuveson DA and Jacks T. Technology advanced cancer modeling in mice. Curr Opin Genet Dev 2002; 12(1): 105-110.
6. Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional strategies for cancer. Am J Pathol 2007; 170: 793-804.
7. Sharpless NE, DePinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nature Rev Drug Discovery 2006; 5: 741-754.
8. Frese KF, Tuveson DA. Maximising mouse cancer models. Nature Rev Cancer 2007; 7: 645-658.
9. Heyer J, Kwong LN, Lowe SW, Chin L. Non-germline genetically engineered mouse models for translational cancer research. Nature Rev Cancer 2010; 10: 470-480.
10. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Reviews Cancer 2008; 8: 147-156.
11. Rangarajan A, Weinberg RA. Comparative biology of mouse versus human cells: modelling human cancer in mice. Nature Rev Cancer 2003; 3: 952-959.
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000: 100: 57-70.
13. Bibby MC. Orthotopic models for cancer for preclinical drug evaluation. Advantages and disadvantages. Eur J Cancer 2004; 40: 852-857.
14. Kubota T. Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic implantation. J Cell Biochem 1994; 56: 4-8.
15. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models an early clinical trials. Br J Cancer 2001; 84: 1424-1431.
16. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003; 9: 4227-4239.
17. Taetle R, Rosen F, Abramson I, Venditti J, Howell S. Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts. Cancer Treat Rep 1987; 71: 297-304.
18. Mattern J, Bak M, Hahn EW, Volm M. Human tumor xenografts as models for drug testing. Cancer Metastasis Rev 1988; 7: 263-284.
19. Bailey MJ, Gazet JC, Smith IE, Steel GG. Chemotherapy of human breast carcinoma xenografts. Br J Cancer 1980; 42: 530-536.
20. Inoue K, Fujiomoto S, Ouawa M. Antitumor efficacy of seventeen anticancer drugs in human breast cancer xenograft (MX-1) transplanted in nude mice. Cancer Chemother Pharmacol 1983; 10: 182-186.
21. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumor xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004: 40: 802-820.
22. Favre R, Marotia L, Drancourt M, et al. 6-Day subrenal capsule assay (SRCA) as a predictor of the response of advanced cancers to chemotherapy. Eur J Cancer Clin Oncol 1986; 22: 1171-1178.
23. Bogden AE, Cobb WR, Lepage DJ, Haskell PM, Gulkin TA, Ward A, Kelton DE, Esber HJ. Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: six-day subrenal capsule assay. Cancer 1981; 48: 10-20.
24. Griffin TW, Bogden AE, Reich SD, et al. Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy. Cancer 1983; 52: 2185-2192.
25. Hunter RE, Reich SD, Griffin TW, Bogden AE. Responsiveness of gynaecologic tumors to chemotherapeutic agents in the 6-day subrenal capsule assay. Gynecol Oncol 1982; 14: 298-306.
26. Dong X, Guan J, English JC, et al. Patient-Derived First Generation Xenografts of Non-Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy. Clin Cancer Res 2010; 16: 1442-1451.
27. Cutz J, Guan J, Bayani J, et al. Establishment in Severe Combined Immunodeficiency Mice of Subrenal Capsule Xenografts and-Transplantable Tumor Lines from a Variety of Primary Human Lung Cancers: Potential Models for Studying Tumor Progression^ Related Changes. Clin Cancer Res 2006; 12: 4043-4054.
28. Takimoto CH. Why drugs fail: of mice and men revisited. Clin Cancer Res 2001; 7: 229-230.
29. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase Itargeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 146-148.
30. Rubin E, Wood V, Bharti A, et al. A Phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1995; 1: 269-276.
31. Dahut W, Harold N, Takimoto C, et al. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 1996; 14: 1236-1244.
32. Kirstein MN, Houghton PJ, Cheshire PJ, et al. Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res 2001; 7: 358-366.
33. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur Cancer 2004; 40: 837-844.
34. Langdon SP, Hendriks HR, Braakhuis BJ, et al. Preclinical phase II studies in human tumor xenografts: a European multicenter followup study. Ann Oncol 1994; 5: 415-422.
35. Boven E, Winograd B, Berger DP, et al. Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res 1992; 52: 5940-5947.
36. Creighton CJ, Cordero KE, Larios JM, et al. Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol 2006; 7: R28.
37. Taylor KJ, Sims AH, Liang L, et al. Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Res 2010; 12(3): R39.
38. Herschkowitz JI, Simin K, Weigmans VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8: R76.
39. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer. JNCI 2004; 96: 926-935.
40. Massarweh S, Osborne CK, Creighton CJ, et al. Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function. Cancer Res 2008; 68: 826-833.
41. Creighton CJ, Massarweh S, Huang S, et al. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 2008; 68: 7493-7501.
42. Arpino G, Gutierrez C, Weiss H, et al. Treatment of human epidermal growth factor receptor 2 overexpressing breast cancer xenografts with multiagent HER-targeted therapy. JNCI 2007; 99: 694-705.
43. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28: 1138-1144.
44. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69: 9330-9336.
45. Brinster RL, Chen HY, Messing A, van Dyke T, Levine AJ, Palmiter RD. Transgenic mice harbouring SV40 T-antigen genes develop characteristic brain tumors. Cell 1984; 37: 367-379.
46. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533-538.
47. Langdon WY, Harris AW, Cory S, Adams JM. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell 1986; 47: 11-18.
48. Ornitz DM, Hammer RE, Messing A, Palmiter RD, Brinster RL. Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. Science 1987; 238: 188-193.
49. Quaife CJ, Pinkert CA, Ornitz DM, Palmiter RD, Brinster RL. Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice. Cell 1987; 48: 1023-1034.
50. Leder A, Pattengale PK, Kuo A, Stewart TA, Leder P. Consequences of widespread deregulation of the c-myc gene in transgenic mice: Multiple neoplasms and normal development. Cell 1986; 45: 485-495.
51. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 1987; 49: 465-475.
52. Lovejoy EA, Clarke AR, Harrison DJ. Animal models and the molecular pathology of cancer. J Pathol 1997; 181: 130-135.
53. Ahmad I, Sansom OJ, Leung HY. Advances in mouse models of prostate cancer. Expert Rev Mol Medicine 2008; 10: E16.
54. Kaspar S. Survey of Genetically Engineered Mouse Models for Prostate Cancer: Analyzing the Molecular Basis of Prostate Cancer Development, Progression and Metastasis. J Cell Biochem 2005; 94: 279-297.
55. Jeet V, Russell PJ and Khatri A. Modeling prostate cancer: a perspective on transgenic mouse models. Cancer Metast Rev 2010; 29: 123-142.
56. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92(8): 3439-3443.
57. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56: 4096-4102.
58. Kasper S, Sheppard PC, Yan Y, et al. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 1998; 78, 319-333.
59. Masumori N, Thomas TZ, Chaurand P, et al. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 2001; 61: 2239-2249.
60. Konno-Takahashi N, Takeuchi T, Nishimatsu H, Kamijo T, Tomita K, Schalken JA. Engineered FGF-2 expression induces glandular epithelial hyperplasia in the murine prostatic dorsal lobe. Eur Urol 2004; 46: 126-132.
61. Polnaszek N, Kwabi-Addo B, Peterson LE, Ozen M, Greenberg NM, Ortega S. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 2003; 63: 5754-5760.
62. Foster BA, Evangelou A, Gingrich JR, Kaplan PJ, DeMayo F, Greenberg NM. Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation 2002; 70: 624-632.
63. Zhang X, Chen MW, Ng A, et al. Abnormal prostate development in C3(1)-bcl-2 transgenic mice. Prostate 1997; 32: 16-26.
64. Kindblom J, Dillner K, Sahlin L, et al. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinol 2003; 144: 2269-2278.
65. Lohnes D, Kastner P, Dierich A, Mark M, LeMeur M, Chambon P. Function of retinoic acid receptor gamma in the mouse. Cell 1993; 73: 643-658.
66. Nevalainen MT, Ahonen TJ, Yamashita H, et al. Epithelial defect in prostates of Stat5a null mice. Lab Invest 2000; 80: 993-1006.
67. Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci USA 2001; 98: 10823-10828.
68. Scherl A, Li JF, Cardiff RD, Schreiber-Agus N. Prostatic intraepithelial neoplasia and intestinal metaplasia in prostates of probasin-RAS transgenic mice. Prostate 2004; 59: 448-459.
69. Song Z, Wu X, Powell WC, et al. Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. Cancer Research 2002; 62: 5096-5105.
70. Freeman KW, Welm BE, Gangula RD, et al. Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Research 2003; 63: 8256-8263.
71. Shim EH, Johnson L, Noh HL, et al. Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res 2003; 63:1583-1588.
72. Majumder PK, Yeh JJ, George DJ, et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model. Proc Natl Acad Sci USA 2003; 100: 7841-7846.
73. Kelavkar UP, Parwani AV, Shappell SB, Martin WD. Conditional expression of human 15-lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: the FLiMP mouse model. Neoplasia 2006; 8: 510-522.
74. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 2002; 62: 2999-3004.
75. Abdulkadir SA, Magee JA, Peters TJ, et al. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 2002; 22: 1495-1503.
76. Maddison LA, Sutherland BW, Barrios RJ, Greenberg NM. Conditional deletion of Rb causes early stage prostate cancer. Cancer Res 2004; 64: 6018-6025.
77. Ellwood-Yen K, Graeber TG, Wongvipat J, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003; 4: 223-238.
78. Bruxvoort KJ, Charbonneau HM, Giambernardi TA, et al. Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res 2007; 67: 2490-2496.
79. Wang S, Gao J, Lei Q, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209-221.
80. You MJ, Castrillon DH, Bastian BC, et al. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci USA 2002; 99: 1455-1460.
81. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis; Nature 2005; 436: 725-730.
82. Zhou Z, Flesken-Nikitin A, Corney DC, et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 2006; 66: 7889-7898.
83. Venkateswaran V, Fleshner NE, Sugar LM, Klotz LH. Antioxidants block prostate cancer in lady transgenic mice. Cancer Research 2004; 64: 5891-5896.
84. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10: 594-601.
85. Wechter WJ, Leipold DD, Murray ED, et al. E-7869 (Rflurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 2000; 60: 2203-2208.
86. Gupta S, Adhami VM, Subbarayan M, et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004; 64: 3334-3343.
87. Harper CE, Patel BB, Wang J, Arabshahi A, Eltoum IA, Lamartiniere CA. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 2007; 28: 1946-1953.
88. Wang J, Eltoum IE, Lamartiniere CA. Genistein chemoprevention of prostate cancer in TRAMP mice. J Carcinog 2007; 6: 3.
89. Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, Mukhtar H. Chemoprevention of prostate carcinogenesis by alphadifluoromethylornithine in TRAMP mice. Cancer Res 2000; 60: 5125-5133.
90. Raghow S, Kuliyev E, Steakley M, Greenberg N, Steiner MS. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model. Cancer Res 2000; 60: 4093-4097.
91. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 2002; 62: 1370-1376.
92. Huss WJ, Lai L, Barrios RJ, Hirschi KK, Greenberg NM. Retinoic acid slows progression and promotes apoptosis of spontaneous prostate cancer. Prostate 2004; 61: 142-152.
93. Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000; 60: 2444-2448.
94. Martiniello-Wilks R, Dane A, Voeks DJ, et al. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J Gene Med 2004; 6: 43-54.
95. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nature Rev Cancer 2007; 7: 659-672.
96. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000; 19: 968-988.
97. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
98. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
99. Bennett CN, Green JE. Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of preclinical models. Breast Cancer Res 2008; 5: 213.
100. Pegram M, Ngo D. Application and potential limitations of animal models used in the development of trastuzumab (herceptin): a case study. Drug Delivery Reviews 2006; 58: 723-734.
101. Green JE, Hudson T. The promise of genetically engineered mice for cancer prevention studies. Nature Rev Cancer 2005; 5: 184-198.
102. Li Y, Zhang Y, Hill J, et al. The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res 2007; 13: 6224-6231.
103. Li Y, Zhang Y, Hill J, et al. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer 2008; 98: 1380-1388.
104. Menard S, Aiello P, Tagliabue E, et al. Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. Cancer Res 2000; 60: 273-275.
105. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001; 98: 12485-12490.
106. Sacco MG, Catò EM, Ceruti R, et al. Systemic gene therapy with antiangiogenic factors inhibits spontaneous breast tumor growth and metastasis in MMTVneu transgenic mice. GeneTher 2001; 8: 67-70.
107. Nanni P, Nicoletti G, De Giovanni C, et al. Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. Int J Cancer 2003; 105: 384-389.
108. Sacco MG, Soldati S, Indraccolo S, et al. Combined antiestrogen, antiangiogenic and anti-invasion therapy inhibits primary and metastatic tumor growth in the MMTVneu model of breast cancer. Gene Ther 2003; 10: 1903-1909.
109. Lu C, Speers C, Zhang Y, et al. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 2003; 95: 1825-1833.
110. Yoshidome K, Shibata M.-A, Couldrey C, Korach KS, Green JE. Estrogen promotes increased mammary tumor development in C3(1)/SV40 Tag transgenic mice: paradoxical loss of ERα expression during tumor development. Cancer Res 2000; 60: 6901-6910.
111. Kavanaugh C, Green JE. Celecoxib delays tumor incidence and multiplicity in the C3(1)/SV40 Large T-antigen transgenic mammary cancer model. Proc. Am. Assoc. Cancer Res 2003; 44, R4885 (abs).
112. Yokoyama Y, Green JE, Sukhatme VP, Ramakrishnan S. Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. Cancer Res 2000; 60: 4362-4365.
113. Huh JI, Calvo A, Stafford J, et al. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through anti-angiogenic and non-antiangiogenic mechanisms. Oncogene 2005; 24: 790-800.
114. Green JE, Shibata MA, Shibata E, et al. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/tantigen transgenic mice. Cancer Res 2001; 61: 7449-7455.
115. Singh M, Lima A, Molina R, et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nature Biotech 2010; 28: 565-593.
116. Yu Q, Sicinska E, Geng Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006; 9: 23-32.
117. Landis MW, Pawlyk BS, Li T, Sicinski P, Hinds PW. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006; 9: 13-22.
118. Politi K, Zakowski MF, Fan P-D, Schonfield EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006; 20: 1496-1510.
119. Ji H, Li D, Chen L, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006; 9: 485-495.
120. Olson P, Hanahan D. Breaching the cancer fortress. Science 2009; 324: 1400-1401.
121. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science 2009; 324: 1457-1461.
122. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Med 2002; 8: 459-465.
123. Threadgill DW, Dlugosz AA, Hansen LA, et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995; 269: 230-234.
124. Zhou Y, Rideout WM, Zi T, et al. Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nature Biotech 2010; 28: 71-78.
125. Varticovski L, Hollingshead MG, Robles AI, et al. Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models. Clin Cancer Res 2007; 13: 2168-2177.
126. Wu M, Jung L, Cooper AB, et al. Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice. Proc Natl Acad Sci USA 2009; 106: 7022-7027.
127. Paolomi M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Rev Cancer 2008; 8: 147-156.
128. Hansen K, Khanna C. Spontaneous and genetically engineered animal models: use in preclinical drug development. Eur J Cancer 2004; 40: 858-880.
129. Dewhirst MW. Animal modeling and thermal dose. Radiol Clin North Am 1989; 27: 509-518.
130. Ladiges WC, Storb R, Thomas ED. Canine models of bone marrow transplantation. Lab Anim Sci 1990; 40: 11-15.
131. Whelan HT, Schmidt MH, Segura AD, et al. The role of photodynamic therapy in posterior fossa brain tumors. A preclinical study in a canine glioma model. J Neurosurg 1993; 79: 562-568.
132. Dow SW, Elmslie RE, Willson AP, Roche L, Gorman C, Potter TA. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest 1998; 101: 2406-2414.
133. Lindblad-Toh K, Wade CM, Mikkelsen TS, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005; 438: 803-819.
134. O'Brien SJ, Murphy WJ. Genomics. A dog's breakfast? Science 2003; 301: 1854-1855.
135. Kirkness EF, Bafna V, Halpern AL, et al. The dog genome:survey sequencing and comparative analysis. Science 2003; 301: 1898-1903.
136. Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 1995; 18: 93-99.
137. Kleinerman ES. Biologic therapy for osteosarcoma using liposomeencapsulated muramyl tripeptide. Hematol Oncol Clin North Am 1995; 9: 927-938.
138. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high dose methotrexate. J Clin Oncol 2005; 23: 2004-2011.
139. Nardin A, Lefebvre ML, Labroquère K, Faure O, Abastado JP. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets 2006; 6(2): 123-133.
140. LeRoy BE, Northrup N. Prostate cancer in dogs: comparative and clinical aspects. Vet Journal 2009; 180: 149-162.
141. Leav I, Schelling KH, Adams JY, Merk FB, Alroy J. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma. Prostate 2001; 48: 210-224.
142. Cornell KK, Bostwick DG, Cooley DM, et al. Clinical and pathologic aspects of spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases. Prostate 2000; 45: 173-183.
143. Waters DJ, Shen S, Cooley DM, et al. Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. JNCI 2003; 95: 237-241.
144. London CA, Kisseberth WC, Galli SJ, et al. Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumours. J Comp Pathol 1996; 115: 399-414.
145. Pryer NK, Lee LB, Zadovaskaya R, et al. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin. Cancer Res 2003; 9: 5729-5734.
146. MacEwen EG. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metast Rev 1990; 9: 125-136.
147. Jeglum KA, DeGuzman E, Young KM. Chemotherapy of advanced mammary adenocarcinoma in 14 cats. J Am Vet Med Assoc 1985; 187: 157-160.
148. Pegram M, Ngo D. Application and potential limitations of animal models used in the development of trastuzumab (herceptin): a case study. Drug Delivery Reviews 2006; 58: 723-734.